Restructuring Plan Implemented To Focus on Cancer Decision Support and Artificial Intelligence Platform Integration of Four Pillars: GPS Cancer, Eviti...
CULVER CITY, Calif.–(BUSINESS WIRE)–Aug. 8, 2017– NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report...
GPS Adoption: GPS Cancer Test to Be Complementary Diagnostic for FDA Authorized Nant Cancer Vaccine Clinical Trials, the First Novel Combination of...
Company adds established oncology expert to leadership team CULVER CITY, Calif. – May 10, 2017 — NantHealth, Inc. (NASDAQ-GS: NH),...
The NANT Cancer Vaccine, The First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic,...
CULVER CITY, Calif.–May 8, 2017– NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will...
Culver City, Calif. – May 3 2017 — NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today...
NantHealth Reports 72% Increase in Full Year 2016 Total Net Revenue
CULVER CITY, Calif.–(BUSINESS WIRE)–Mar. 28, 2017– NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report...
CULVER CITY, Calif.–Mar. 16, 2017– NantHealth and Dr. Patrick Soon-Shiong today sent two detailed letters to Statnews.com, listing inaccuracies of...
Patrick Soon-Shiong, MD, CEO and founder of NantHealth, has been awarded the Intelligent Health Association (IHA) Special Recognition Award. The...
Culver City, Calif. – February 28, 2017 — NantHealth, Inc. (NASDAQ-GS: NH),